Understanding the rate of lymphocyte replication and destruction in human immunodeficiency virus (HIV)-infected patients, as well as the effects of therapy on lymphocyte replication should lead to a better understanding of the mechanisms behind the immunodeficiency induced by HIV. Little is known about the replication rate in healthy as well as HIV-infected patients. Two approaches are being used to address this issue. First, healthy, as well as HIV-infected, patients will receive up to 5 days of continuous infusions with [6,6-2H2]-glucose, a nonradioactive, stable isotope of glucose that is safe to administer. The deuterium is incorporated into DNA via metabolism of glucose to ribose and incorporation into nucleotides. The rate of incorporation can be measured in subpopulations of cells to determine the rate of replication of those cells, and the rate of loss of the incorporated deuterium can be used to examine the turnover rate of the replicated cells. A second approach will involve administering bromodeoxyuridine (BrDU; 200 mg/m2), an analogue of thymidine, to HIV-infected patients. BrDU is incorporated into DNA and incorporation can be measured using an anti-BrDU monoclonal antibody. By FACS analysis, both surface markers and BrDU can be measured. Thus, FACS analysis can be used directly to measure subpopulations of cells that have replicated. These two approaches complement each other and should provide information about lymphocyte kinetics that will have relevance to HIV infection as well as other disease states.
